@article{JTD27650,
author = {Yongshun Chen and Xinyu Cheng and Haixia Song and Abraham J. Wu and Geoffrey Y. Ku and Percy Lee and Marije Slingerland and Kazuo Koyanagi and Shaobo Ke and Hu Qiu and Wei Shi and Yi Gao and Jiamei Chen and written on behalf of AME Radiation Oncology Collaborative Group},
title = {Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {4},
year = {2019},
keywords = {},
abstract = {Background: The potential survival benefits of adding radiotherapy to systemic therapy for esophageal cancer patients with oligometastases are unknown.
Methods: In this retrospective analysis, patients with stage IV esophageal cancer (according to the American Joint Committee on Cancer Seventh edition staging system) with ≤3 metastases who underwent chemotherapy with cisplatin/paclitaxel between 2012 and 2015 were identified. Patients received chemotherapy (CT) alone vs. concurrent chemoradiotherapy (CCRT) to all metastases.
Results: Of 461 patients, 97% had squamous cell cancer. One hundred and ninety-six patients (42.5%) received CCRT and 265 (57.5%) underwent CT alone. At week 8, there were 3 (1.5%) complete responses (CR) and 95 (48.5%) partial responses (PR) in the CCRT group, compared to 3 (1.1%) CR and 102 (38.5%) PR in the CT alone group. The overall rate of improvement in dysphagia score was noted in 78.5% of patients in the CCRT group versus 61.5% in the CT alone group (P=0.014). A statistically significant difference was demonstrated in disease control rate between the two groups (81.6% vs. 64.5%, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/27650}
}